CoChat
Sign Up
Cited by 719

The DOI matches its Crossref record.

The Protein C Pathway

Esmon, Charles T.·2003·Chest
DOI 10.1378/chest.124.3_suppl.26s
Open this paper in CoChat — free account

Abstract

The protein C anticoagulant pathway serves as a major system for controlling thrombosis, limiting inflammatory responses, and potentially decreasing endothelial cell apoptosis in response to inflammatory cytokines and ischemia. The essential components of the pathway involve thrombin, thrombomodulin, the endothelial cell protein C receptor (EPCR), protein C, and protein S. Thrombomodulin binds thrombin, directly inhibiting its clotting and cell activation potential while at the same time augmenting protein C (and thrombin activatable fibrinolysis inhibitor [TAFI]) activation. Furthermore, thrombin bound to thrombomodulin is inactivated by plasma protease inhibitors > 20 times faster than free thrombin, resulting in increased clearance of thrombin from the circulation. The inhibited thrombin rapidly dissociates from thrombomodulin, regenerating the anticoagulant surface. Thrombomodulin also has direct anti-inflammatory activity, minimizing cytokine formation in the endothelium and decreasing leukocyte-endothelial cell adhesion. EPCR augments protein C activation approximately 20-fold in vivo by binding protein C and presenting it to the thrombin-thrombomodulin activation complex. Activated protein C (APC) retains its ability to bind EPCR, and this complex appears to be involved in some of the cellular signaling mechanisms that down-regulate inflammatory cytokine formation (tumor necrosis factor, interleukin-6). Once APC dissociates from EPCR, it binds to protein S on appropria…

Overview

Integrity signals

Registry

Crossref · 10.1378/chest.124.3_suppl.26s

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 54

  1. Shen, 1994, Factor V and protein S as synergistic cofactors to activated protein C in degradation of factor VIIIa, J Biol Chem, 269, 18735, 10.1016/S0021-9258(17)32228-7 · DOI
  2. Taylor, 2001, Endothelial cell protein C receptor plays an important role in protein C activationin vivo, Blood, 97, 1685, 10.1182/blood.V97.6.1685 · DOI
  3. Rezaie, 1995, Protein C inhibitor is a potent inhibitor of the thrombin-thrombomodulin complex, J Biol Chem, 270, 25336, 10.1074/jbc.270.43.25336 · DOI
  4. Regan, 1996, The endothelial cell protein C receptor: inhibition of activated protein C anticoagulant function without modulation of reaction with proteinase inhibitors, J Biol Chem, 271, 17499, 10.1074/jbc.271.29.17499 · DOI
  5. Riewald, 2002, Activation of endothelial cell protease activated receptor 1 by the protein C pathway, Science, 296, 1880, 10.1126/science.1071699 · DOI
  6. Cheng, 2003, Activated protein C blocks p53-mediated apoptosis in ischemic human brain endothelium and is neuroprotective, Nat Med, 9, 338, 10.1038/nm826 · DOI
  7. Bajzar, 1996, TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex, J Biol Chem, 271, 16603, 10.1074/jbc.271.28.16603 · DOI
  8. Campbell, 2001, Carboxypeptidase R is an inactivator of complement-derived inflammatory peptides and an inhibitor of fibrinolysis, Immunol Rev, 180, 162, 10.1034/j.1600-065X.2001.1800114.x · DOI
  9. Campbell, 2002, Inactivation of C3a and C5a octapeptides by carboxypeptidase R and carboxypeptidase N, Microbiol Immunol, 46, 131, 10.1111/j.1348-0421.2002.tb02669.x · DOI
  10. Conway, 2002, The lectin-like domain of thrombomodulin confers protection from neutrophil-mediated tissue damage by suppressing adhesion molecule expression via nuclear factor κB and mitogen-activated protein kinase pathways, J Exp Med, 196, 565, 10.1084/jem.20020077 · DOI
  11. Hamada, 1995, The epidermal growth factor-like domain of recombinant human thrombomodulin exhibits mitogenic activity for Swiss 3T3 cells, Blood, 86, 225, 10.1182/blood.V86.1.225.bloodjournal861225 · DOI
  12. Suzuki, 1989, A domain composed of epidermal growth factor-like structures of human thrombomodulin is essential for thrombin binding and for protein C activation, J Biol Chem, 264, 4872, 10.1016/S0021-9258(18)83672-9 · DOI
  13. Esmon, 1989, The roles of protein C and thrombomodulin in the regulation of blood coagulation, J Biol Chem, 264, 4743, 10.1016/S0021-9258(18)83649-3 · DOI
  14. Bourin, 1993, Glycosaminoglycans and the regulation of blood coagulation, Biochem J, 289, 313, 10.1042/bj2890313 · DOI
  15. Oganesyan, 2002, The crystal structure of the endothelial protein C receptor and a bound phospholipid, J Biol Chem, 277, 24851, 10.1074/jbc.C200163200 · DOI
  16. Fukudome, 1994, Identification, cloning, and regulation of a novel endothelial cell protein C/activated protein C receptor, J Biol Chem, 269, 26486, 10.1016/S0021-9258(18)47220-1 · DOI
  17. Moody, 2000, CD1c-mediated T-cell recognition of isoprenoid glycolipids inMycobacterium tuberculosis infection, Nature, 404, 884, 10.1038/35009119 · DOI
  18. Hong, 1999, Lipid antigen presentation in the immune system: lessons learned from CD1d knockout mice, Immunol Rev, 169, 31, 10.1111/j.1600-065X.1999.tb01304.x · DOI
  19. Taylor, 2000, The endothelial cell protein C receptor aids in host defense againstEscherichia coli sepsis, Blood, 95, 1680, 10.1182/blood.V95.5.1680.005k33_1680_1686 · DOI
  20. Xu, 2000, Metalloproteolytic release of endothelial cell protein C receptor, J Biol Chem, 275, 6038, 10.1074/jbc.275.8.6038 · DOI
  21. Kurosawa, 1998, Plasma levels of endothelial cell protein C receptor are elevated in patients with sepsis and systemic lupus erythematosus: lack of correlation with thrombomodulin suggests involvement of different pathological processes, Blood, 91, 725, 10.1182/blood.V91.2.725 · DOI
  22. Kurosawa, 2000, The soluble endothelial protein C receptor binds to activated neutrophils: involvement of proteinase-3 and CD11b/CD18, J Immunol, 165, 4697, 10.4049/jimmunol.165.8.4697 · DOI
  23. Esmon, 2000, The endothelial cell protein C receptor, Thromb Haemost, 83, 639, 10.1055/s-0037-1613883 · DOI
  24. Mann, 2003, Factor V: a combination of Dr Jekyll and Mr Hyde, Blood, 101, 20, 10.1182/blood-2002-01-0290 · DOI
  25. Nicolaes, 2002, Factor V and thrombotic disease: description of a Janus-faced protein, Arterioscler Thromb Vasc Biol, 22, 530, 10.1161/01.ATV.0000012665.51263.B7 · DOI
  26. Laszik, 1997, Human protein C receptor is present primarily on endothelium of large blood vessels: implications for the control of the protein C pathway, Circulation, 96, 3633, 10.1161/01.CIR.96.10.3633 · DOI
  27. Murakami, 1997, Activated protein C prevents LPS-induced pulmonary vascular injury by inhibiting cytokine production, Am J Physiol, 272, L197
  28. Hancock, 1995, Binding of activated protein C to a specific receptor on human mononuclear phagocytes inhibits intracellular calcium signaling and monocyte-dependent proliferative responses, Transplantation, 60, 1525, 10.1097/00007890-199560120-00026 · DOI
  29. Murphy, 2001, Activated protein C inhibits upregulation of both tissue factor and TNFα in endotoxin stimulated monocytes, Throm Haemost, P509
  30. Shua, 2000, Activated protein C suppresses tissue factor expression on U937 cells in the endothelial protein C receptor-dependent manner, FEBS Lett, 477, 208, 10.1016/S0014-5793(00)01740-3 · DOI
  31. Ishii, 1986, Thrombomodulin, an endothelial anticoagulant protein, is absent from the human brain, Blood, 67, 362, 10.1182/blood.V67.2.362.362 · DOI
  32. Esmon, 2001, Protein C anticoagulant pathway and its role in controlling microvascular thrombosis and inflammation, Crit Care Med, 29, S48, 10.1097/00003246-200107001-00018 · DOI
  33. Esmon, 1981, Identification of an endothelial cell cofactor for thrombin-catalyzed activation of protein C, Proc Natl Acad Sci U S A, 78, 2249, 10.1073/pnas.78.4.2249 · DOI
  34. Dreyfus, 1991, Treatment of homozygous protein C deficiency and neonatal purpura fulminans with a purified protein C concentrate, N Engl J Med, 325, 1565, 10.1056/NEJM199111283252207 · DOI
  35. Rivard, 1995, Treatment of purpura fulminans in meningococcemia with protein C concentrate, J Pediatr, 126, 646, 10.1016/S0022-3476(95)70369-1 · DOI
  36. Smith, 1997, Use of protein C concentrate, heparin, and haemodiafiltration in meningococcus-induced purpura fulminans, Lancet, 350, 1590, 10.1016/S0140-6736(97)06356-3 · DOI
  37. Smith, 1999, Infectious purpura fulminans: diagnosis and treatment, Br J Haematol, 104, 202, 10.1046/j.1365-2141.1999.01186.x · DOI
  38. Conway, 1988, Tumor necrosis factor suppresses transcription of the thrombomodulin gene in endothelial cells, Mol Cell Biol, 8, 5588
  39. Glaser, 1992, Oxidation of a specific methionine in thrombomodulin by activated neutrophil products blocks cofactor activity: a potential rapid mechanism for modulation of coagulation, J Clin Invest, 90, 2565, 10.1172/JCI116151 · DOI
  40. Takano, 1990, Plasma thrombomodulin in health and diseases, Blood, 76, 2024, 10.1182/blood.V76.10.2024.2024 · DOI
  41. Faust, 2001, Dysfunction of endothelial protein C activation in severe meningococcal sepsis, N Engl J Med, 345, 408, 10.1056/NEJM200108093450603 · DOI
  42. Liaw, 2003, A monoclonal antibody against activated protein C allows rapid detection of activated protein C in plasma and reveals a calcium ion dependent epitope involved in factor Va inactivation, J Thromb Haemost, 1, 662, 10.1046/j.1538-7836.2003.00153.x · DOI
  43. Gu, 2000, Endotoxin and thrombin elevate rodent endothelial cell protein C receptor mRNA levels and increase receptor sheddingin vivo, Blood, 95, 1687, 10.1182/blood.V95.5.1687.005k08_1687_1693 · DOI
  44. Slungaard, 1993, Eosinophil cationic granule proteins impair thrombomodulin function: a potential mechanism for thromboembolism in hypereosinophilic heart disease, J Clin Invest, 91, 1721, 10.1172/JCI116382 · DOI
  45. Slungaard, 1994, Platelet factor 4 stimulates thrombomodulin protein C-activating cofactor activity: a structure-function analysis, J Biol Chem, 269, 25549, 10.1016/S0021-9258(18)47284-5 · DOI
  46. Taylor, 1987, Protein C prevents the coagulopathic and lethal effects ofEscherichia coli infusion in the baboon, J Clin Invest, 79, 918, 10.1172/JCI112902 · DOI
  47. Bernard, 2001, Efficacy and safety of recombinant human activated protein C for severe sepsis, N Engl J Med, 344, 699, 10.1056/NEJM200103083441001 · DOI
  48. Solymoss, 1988, Kinetics of inactivation of membrane-bound factor Va by activated protein C: protein S modulates factor Xa protection, J Biol Chem, 263, 14884, 10.1016/S0021-9258(18)68121-9 · DOI
  49. Okajima, 2001, Regulation of inflammatory responses by natural anticoagulants, Immunol Rev, 184, 258, 10.1034/j.1600-065x.2001.1840123.x · DOI
  50. Laszik, 2003, Thrombomodulin (TM) but not endothelial cell protein receptor (EPCR) mRNA is downregulated in streptozotocin-induced diabetic rat kidneys [abstract], Mod Pathol, 16, 267A
  51. Kim, 2002, Early loss of thrombomodulin expression impairs vein graft thromboresistance: implications for vein graft failure, Circ Res, 90, 205, 10.1161/hh0202.105097 · DOI
  52. Laszik, 2001, Down-regulation of endothelial expression of endothelial cell protein C receptor and thrombomodulin in coronary atherosclerosis, Am J Pathol, 159, 797, 10.1016/S0002-9440(10)61753-1 · DOI
  53. Ohdama, 1994, Plasma thrombomodulin in Wegener's granulomatosis as an indicator of vascular injuries, Chest, 106, 666, 10.1378/chest.106.3.666 · DOI
  54. Waugh, 2000, Thrombomodulin overexpression to limit neointima formation, Circulation, 102, 332, 10.1161/01.CIR.102.3.332 · DOI

Cited by

Sorted by citations

Metadata

Authors
Esmon, C. T.
Venue
Chest
Publisher
Elsevier BV
Published
2003-09
Volume
124
Issue
3
Pages
26S-32S
ISSN
0012-3692
DOI
10.1378/chest.124.3_suppl.26s
Cited by
719
References
0
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review